Hussman Strategic Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.46M | Sell |
10,500
-4,200
| -29% | -$588K | 0.32% | 147 |
|
|
2025
Q4 | $1.8M | Sell |
14,700
-6,300
| -30% | -$766K | 0.44% | 106 |
|
|
2025
Q3 | $2.33M | Hold |
21,000
| – | – | 0.5% | 67 |
|
|
2025
Q2 | $2.33M | Buy |
+21,000
| New | +$2.23M | 0.53% | 74 |
|
|
2024
Q3 | – | Sell |
-42,000
| Closed | -$2.88M | – | 255 |
|
|
2024
Q2 | $2.88M | Hold |
42,000
| – | – | 0.79% | 35 |
|
|
2024
Q1 | $3.08M | Hold |
42,000
| – | – | 0.72% | 52 |
|
|
2023
Q4 | $3.4M | Hold |
42,000
| – | – | 0.77% | 32 |
|
|
2023
Q3 | $3.15M | Buy |
42,000
+4,400
| +12% | +$338K | 0.6% | 45 |
|
|
2023
Q2 | $2.9M | Buy |
37,600
+12,800
| +52% | +$1.02M | 0.53% | 46 |
|
|
2023
Q1 | $2.06M | Hold |
24,800
| – | – | 0.32% | 126 |
|
|
2022
Q4 | $2.13M | Sell |
24,800
-6,400
| -21% | -$507K | 0.35% | 113 |
|
|
2022
Q3 | $1.93M | Hold |
31,200
| – | – | 0.33% | 120 |
|
|
2022
Q2 | $1.93M | Hold |
31,200
| – | – | 0.33% | 108 |
|
|
2022
Q1 | $1.85M | Hold |
31,200
| – | – | 0.36% | 108 |
|
|
2021
Q4 | $2.27M | Buy |
+31,200
| New | +$2.15M | 0.5% | 69 |
|
|
2021
Q1 | – | Sell |
-20,400
| Closed | -$1.19M | – | 345 |
|
|
2020
Q4 | $1.19M | Buy |
+20,400
| New | +$1.23M | 0.31% | 128 |
|
|
2020
Q2 | – | Sell |
-41,150
| Closed | -$3.08M | – | 284 |
|
|
2020
Q1 | $3.08M | Buy |
+41,150
| New | +$2.84M | 0.83% | 12 |
|
|
2019
Q1 | – | Sell |
-800
| Closed | -$50K | – | 254 |
|
|
2018
Q4 | $50K | Sell |
800
-25,000
| -97% | -$1.75M | 0.01% | 238 |
|
|
2018
Q3 | $1.99M | Sell |
25,800
-25,000
| -49% | -$1.89M | 0.58% | 72 |
|
|
2018
Q2 | $3.6M | Hold |
50,800
| – | – | 0.97% | 23 |
|
|
2018
Q1 | $3.83M | Buy |
+50,800
| New | +$4.04M | 1.06% | 18 |
|
|
2017
Q3 | – | Sell |
-25,000
| Closed | -$1.77M | – | 213 |
|
|
2017
Q2 | $1.77M | Sell |
25,000
-25,000
| -50% | -$1.66M | 0.39% | 94 |
|
|
2017
Q1 | $3.4M | Buy |
+50,000
| New | +$3.52M | 0.75% | 62 |
|
|
2015
Q4 | – | Sell |
-75,000
| Closed | -$7.36M | – | 213 |
|
|
2015
Q3 | $7.36M | Hold |
75,000
| – | – | 0.93% | 37 |
|
|
2015
Q2 | $8.78M | Buy |
+75,000
| New | +$8.2M | 1.01% | 36 |
|
|
2013
Q4 | – | Sell |
-250,000
| Closed | -$15.7M | – | 212 |
|
|
2013
Q3 | $15.7M | Sell |
250,000
-100,000
| -29% | -$5.98M | 0.86% | 56 |
|
|
2013
Q2 | $17.9M | Buy |
+350,000
| New | +$18.2M | 0.82% | 49 |
|
Other funds holding GILD
VCM
VPM
Hussman Strategic Advisors's GILD Position: Q1 2026 in Review
Hussman Strategic Advisors reduced its Gilead Sciences (GILD) stake by 29% in Q1 2026, selling an estimated $588K and leaving 10,500 shares worth $1.46M. The position accounts for 0.32% of the portfolio, ranked #147.
Hussman Strategic Advisors first reported a position in GILD in Q2 2013 and has held it in 27 quarters since. The position peaked at $17.9M in Q2 2013. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Hussman Strategic Advisors held 10,500 shares of Gilead Sciences worth $1.46M as of Q1 2026.
- Hussman Strategic Advisors sold 4,200 Gilead Sciences shares in Q1 2026, an estimated $588K.
- Gilead Sciences made up 0.32% of Hussman Strategic Advisors's portfolio in Q1 2026, its #147 holding.
- Hussman Strategic Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 27 quarters since.
- Hussman Strategic Advisors's Gilead Sciences position peaked at $17.9M in Q2 2013.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.